Friends and fitness: key to life after cancer?
NCT ID NCT07259304
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better support young survivors through social and exercise programs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could point to better ways to support young cancer survivors through social connections and physical activity.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any drug or therapy, so it cannot directly improve health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
118 people
The number who actually took part.
- Started
-
Nov 2021
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.
- Ages
-
18 to 39 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-39 years at cancer diagnosis. * Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer. * Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging). * Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center. * Clinician assessed expected survival greater than 12 months at time of diagnosis. * Able to complete questionnaires and wear a wrist worn accelerometer. * English or Spanish speaking. Exclusion Criteria: * Leukemia (excluded due to longer treatment duration and different care trajectory). * Primary language other than English or Spanish. * Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anatomic stage I breast cancer ajcc V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Drug attack on Hard-to-Treat lymphomas
- PET scans guide Nivolumab-Chemo combo in relapsed hodgkin lymphoma
- Patient's own t cells engineered to hunt lymphoma in early trial
- Broccoli compound put to the test against melanoma
- Can a vaccine stop GI cancers from returning?
- Immunotherapy injection tested against Hard-to-Treat childhood lymphoma